Before revision: Clinical trials A Phase I/II study completed in 2008 evaluating NV1020 for treatment of metastatic colorectal cancer in the liver.The study assessed tumour response by CT scan and FDG-PET scans, showing 67%DIF < of patients had an initial increase in tumour size then followed by a decrease in 64% of patients.
After revision: Clinical trials As células cancerígenas têm sua capacidade de aderência reduzida , aumentando a exposição do receptor Nectina-1 .Dentro desse contexto, a versão NV1020 for treatment of metastatic colorectal cancer in the liver.The study assessed tumour response by CT scan and FDG-PET scans, showing 67%DIF < of patients had an initial increase in tumour size then followed by a decrease in 64% of patients.